Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott To Market Ditropan XL For Five Years: Deal Parallels Alza Merger

Executive Summary

Abbott's co-promotion agreements for Ditropan XL with Alza ensure that Abbott will continue to detail the once-daily overactive bladder treatment for the next five years even if the companies do not complete their proposed merger.

You may also be interested in...



Abbott And Alza Will Discuss Ditropan XL Copromotion In Merger Post-Mortem

Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.

Abbott And Alza Will Discuss Ditropan XL Copromotion In Merger Post-Mortem

Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.

Abbott Diagnostics Manufacturing Issues Could Decrease Alza Merger Value

Abbott's pending merger with Alza could give FDA leverage in discussions over quality control problems in Abbott's diagnostics business.

Related Content

UsernamePublicRestriction

Register

PS034737

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel